Clinical trials: Breast Cancer, Breast Neoplasms
Physical Activity, Cancer Survivor
Move 2 Health: A Couple-Based Physical Activity Intervention for Cancer Survivors
This pilot study will develop and test a couple-based physical activity intervention among cancer survivors and their partners. Aim 1: To determine the feasibility and acceptability of a couple-based physical activity…
- Trial name
- NCT03266718
- Testing
- Physical Activity Intervention
- Volunteers
- 40 people
- Sponsor
- Duke University
Signs and Symptoms, Neoplasms
Guarana (Paullinia Cupana) for Breast Cancer Chemotherapy-related Fatigue
The investigators hypothesize that Guaraná, a native plant from the Amazon, might improve chemotherapy-induced fatigue in breast cancer patients undergoing treatment.
- Conditions
- Signs and Symptoms, Neoplasms, Neoplasms by Site, Fatigue
- Trial name
- NCT01043913
- Testing
- Guarana extract
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Faculdade de Medicina do ABC
Breast Cancer
The Immersive Experience of Virtual Reality During Chemotherapy in Patients With Early Breast and Gynecological Cancers: the Patient's Dream Study
"Patient's dream" study is a two-arm randomized controlled trial that will be conducted at Regina Elena National Cancer Institute, IRCCS (Rome), from April 2019 to January 2020.
- Trial name
- NCT05234996
- Testing
- 3 Virtual Reality headset (VR Headset),
- Where
- Italy
- Volunteers
- 44 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
HER2-zero, HER2-low and HER2-positive Tumors Distribution Across HR Expression Categories
Clinico-pathological and Genomic Features of HER2-low Early Breast Cancer
Although breast cancer remains one of the most common and fatal cancer types among women worldwide, earlier diagnosis and improved therapeutic approaches have led to decreased mortality over last years.
- Trial name
- NCT07561346
- Where
- Greece
- Volunteers
- 3,648 people
- Sponsor
- Hellenic Cooperative Oncology Group
Breast Cancer Recurrent
S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer
To compare the progression free survival(PFS) and safety of TS-S vs. TX-X in Patients With Advanced Breast Cancer first-line treatment
- Trial name
- NCT02947061
- Testing
- S1 plus Docetaxel, Capecitabine plus Docetaxel
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Chinese Academy of Medical Sciences
Breast Cancer
Evaluation of EnVisio SmartClip for Intraoperative Localization of Breast Masses
This is a pilot study to estimate the success of the SmartClip device for accurate placement and reproducibility of intraoperative identification of in-breast lesions and for excision utilizing surgical navigation indicators.
- Trial name
- NCT04604561
- Testing
- EnVisio SmartClip, EnVisio™ Navigation System
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Cancer, Colorectal Cancer
Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer
RATIONALE: Printed educational materials, such as the Facing Forward Series: Life After Cancer Treatment manual, may help make the transition from cancer patient to cancer survivor easier in patients who are finishing treatment…
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Malignant Mesothelioma
- Trial name
- NCT00372840
- Testing
- educational intervention, psychosocial assessment and care, quality-of-life assessment
- Where
- United States
- Volunteers
- 340 people
- Sponsor
- Fox Chase Cancer Center
Advanced Solid Tumor, Advanced Breast Cancer
IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors
This trial is a first-in-human, open label, multi-center, dose escalation phase 1a study followed by a disease-specific dose expansion phase 1b study to evaluate the safety, efficacy, and pharmacokinetics (PK) of IMM2902, a…
- Conditions
- Advanced Solid Tumor, Advanced Breast Cancer, Advanced Gastric Cancer
- Trial name
- NCT05076591
- Testing
- IMM2902
- Where
- 3 sites in United States
- Volunteers
- 135 people
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
HER2-positive Metastatic Breast Cancer
Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer
This is an open-label, multicenter, dose-escalation and parallel-group expansion Phase II clinical trial to evaluate the efficacy, safety and tolerability of KN026 in combination with palbociclib and fulvestrant in women or male…
- Trial name
- NCT04778982
- Testing
- KN026 combined with Palbociclib and Fulvestrant
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Metastatic Breast Cancer
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of SKB264 in patients with unresectable locally advanced, recurrent, or metastatic HR+/HER2- breast cancer.
- Trial name
- NCT06081959
- Testing
- SKB264, Eribulin, Capecitabine
- Where
- China
- Volunteers
- 376 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Prostate-specific Membrane Antigen Positive Tumors, Prostate Cancer
A Pilot Study of [Ga-68]PSMA PET/MRI for the Assessment of PSMA-positive Tumors
The purpose of this study is to see if positron emission tomography/ magnetic resonance imaging (PET/MRI) can be used to monitor the effectiveness of cancer treatment using an investigational radioactive drug called [Ga-68]PSMA.
- Conditions
- Prostate-specific Membrane Antigen Positive Tumors, Prostate Cancer, Breast Cancer, Lung Cancer
- Trial name
- NCT02978586
- Testing
- [Ga-68]PSMA PET/MR
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Case Comprehensive Cancer Center
Metastatic Breast Cancer
Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study
Women with recurrent or metastatic breast cancer who are hormone receptor positive are candidates for first line hormonal therapy including aromatase inhibitors.
- Trial name
- CONCEPT (NCT04012918)
- Testing
- Capecitabine plus aromatase inhibitor, A.I.
- Where
- Egypt
- Volunteers
- 124 people
- Sponsor
- Ain Shams University
Breast Cancer, Health Behavior
Effect of Planned Education on Health Beliefs and Fatalism in Women at High Risk of Breast Cancer
Purpose: This project aims to examine the effects of planned education on health beliefs and fatalism in women at high risk of breast cancer.
- Conditions
- Breast Cancer, Health Behavior, Breast Self-Examination
- Trial name
- NCT06690320
- Testing
- IMPLEMENTATION OF A PLANNED EDUCATION PROGRAM ON HEALTH BELIEF MODEL AND FATUALIST TENDENCIES IN WOMEN AT HIGH RISK OF BREAST CANCER
- Where
- Turkey (Türkiye)
- Volunteers
- 72 people
- Sponsor
- Ege University
Breast Cancer
Study on the Efficacy and Safety of "Body-Tuning, Voice-Tuning, Mind-Tuning" Three-Dimensional Integrated Art Therapy in Regulating the Physical-Mental-Social Status of Young and Middle-Aged Breast Cancer Patients After Surgery
To evaluate the improvement effect of the "Body-Tuning, Voice-Tuning, Mind-Tuning" three-dimensional integrated art therapy on insomnia and physical-mental-social status in breast cancer patients aged ≤45 years, and to explore…
- Trial name
- ArtRehab (NCT07815262)
- Testing
- ArtRehab
- Where
- China
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Keda Yu
Breast Cancer
An AI Model Predicts the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer: a Multicenter, Bidirectional Cohort Study
Neoadjuvant chemotherapy is an important part of the systematic treatment of breast cancer, and it is of great clinical significance to predict the efficacy of neoadjuvant chemotherapy in early stage.
- Trial name
- NCT06510127
- Where
- China
- Volunteers
- 840 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Estrogen Receptor Positive, Primary or Recurrent Breast Carcinoma
Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy
This clinical trial studies use of F-18 16 alpha-fluoroestradiol ([F-18] FES) positron emission tomography (PET)/computed tomography (CT) in measuring tumor hormone receptor expression in patients undergoing endocrine-targeted…
- Conditions
- Estrogen Receptor Positive, Primary or Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT04692103
- Testing
- F-18 16 Alpha-Fluoroestradiol, Positron Emission Tomography, Computed Tomography
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Washington
Breast Cancer, Colorectal Cancer
A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies
This is a Phase 2, open-label, multicenter study whose principal objectives are to evaluate the efficacy and safety/tolerability of poziotinib in five cohorts of 30 previously-treated patients each.
- Conditions
- Breast Cancer, Colorectal Cancer, Solid Tumor, Glioblastome Multiforme
- Trial name
- NCT04172597
- Testing
- Poziotinib Hydrochloride, Loperamide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Breast Cancer
A Study of A166 in Patients With Advanced Solid Malignant Tumors
This is a single arm, open-label, dose-escalation and dose-expansion phase I study evaluating A166 in patients with HER2-expressing locally advanced or metastatic solid tumors.
- Trial name
- NCT05311397
- Testing
- A166
- Where
- China
- Volunteers
- 129 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Breast Cancer
The Effect of Dexmedetomidine of the Immune System
The goal of this research study is to learn about how dexmedetomidine (a standard of care sedative) affects your immune system (your defenses against cancer) by measuring your white blood cell levels before and after surgery.
- Trial name
- NCT01692210
- Testing
- Dexmedetomidine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
HER2-positive Metastatic Breast Cancer, Locally Advanced HER2 Positive Breast Carcinoma
Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer
Breast cancer (BC) is the most common neoplasm in the world. In Spain, one in 8 women is diagnosed with BC. The human epidermal growth factor receptor 2 (HER2)-positive BC subtype (that represents around 20% of all BC) was…
- Trial name
- TrasTUCAN (NCT05583110)
- Testing
- Tucatinib, Trastuzumab, Vinorelbine
- Where
- 18 sites in Spain
- Volunteers
- 13 people
- Sponsor
- Spanish Breast Cancer Research Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.